Carsten Thiel: Impactful Medicine

Carsten Thiel: Impactful Medicine – Medical Daily Times

As a visionary within the realm of biotechnology, Carsten Thiel’s leadership, expertise, and professional experience has been parlayed into the successful launch of various high-profile medical products, such as Strensiq, Prolia, Vectibix and Neulasta. Not only has he spearheaded the market launch of many medical breakthrough therapies, but his direct involvement has improved the lives of thousands of patients.

EUSA Pharma Announces Appointment of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development

EUSA Pharma Announces Appointment of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development | Markets Insider

HEMEL HEMPSTED, England and BOSTON, May 15, 2019 /PRNewswire/ — EUSA Pharma (EUSA), a global biopharmaceutical company focused on oncology and rare disease, today announced the strengthening of its senior leadership team with the appointments of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development.

EUSA Pharma Announces Appointment of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development

EUSA Pharma Announces Appointment of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development

HEMEL HEMPSTED, England and BOSTON, May 15, 2019 /PRNewswire/ — EUSA Pharma (EUSA), a global biopharmaceutical company focused on oncology and rare disease, today announced the strengthening of its senior leadership team with the appointments of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development.

EUSA Pharma bolsters senior leadership team with two appointments

EUSA Pharma bolsters senior leadership team with two appointments

Published on: 15/05/19 Rare disease and oncology biopharma firm EUSA Pharma has revealed two new additions to its senior leadership team in two newly-created roles: Dr Carsten Thiel as President Europe and Dr Darrel P Cohen as Head of Clinical Development. In his new role, Dr Thiel will be responsible for leading EUSA’s growing commercial infrastructure in Europe.